Novo Nordisk (Novo Nordisk (NVO)) had a busy Monday morning, rolling out a stack of data that reinforces its position in the diabetes and weight-loss wars. The company presented results from its Phase 3 REIMAGINE 1-3 trials for CagriSema, an investigational once-weekly combo that pairs a novel amylin analog with a GLP-1 receptor agonist. Across all three studies, CagriSema hit its primary endpoint of reducing HbA1c and also nailed the secondary endpoints related to weight loss. The drug was tested at two doses — 2.4 mg/2.4 mg and 1 mg/1 mg — and both showed meaningful improvements in blood sugar control and body weight compared to the study comparators.

But that wasn't the only news. Over the weekend, Novo Nordisk also shared Phase 2 data for zenagamtide (also known as amycretin), another investigational drug. The study met its primary endpoint, showing improvements in HbA1c across all tested doses after 36 weeks. For doses of 1.5 mg and higher, the drug also achieved a key supportive secondary endpoint related to body weight reduction versus placebo. Starting from a baseline HbA1c of 7.8%, participants saw dose-dependent and statistically significant reductions. The 40 mg dose was the star: an estimated mean HbA1c change of -1.71%, with up to 89.1% of participants getting their HbA1c below 7% and 76.2% reaching 6.5% or lower. On the weight front, the 40 mg group lost an average of 14.6% of body weight, compared to just 2.1% for placebo. Novo Nordisk noted that at higher doses, there was no apparent weight-loss plateau by week 36. The company plans to kick off a Phase 3 program for zenagamtide in adults with Type 2 diabetes in the second half of 2026.

Novo Nordisk also presented real-world evidence comparing two treatment strategies for patients already on semaglutide 1 mg: escalating to semaglutide 2 mg versus switching to tirzepatide from Eli Lilly (Eli Lilly (LLY)). After one year, both groups had similar rates of achieving HbA1c below 7%. But the semaglutide 2 mg group had a statistically significant edge in hitting at least 5% weight loss. That's a nice little data point for doctors deciding what to do when patients need more oomph.

And then there's the Wegovy pill. On Sunday, Novo Nordisk announced that Wegovy (semaglutide) tablets 25 mg have surpassed three million prescriptions in just over five months since their January 2026 launch. The company says that works out to roughly one prescription filled every five seconds. That's a lot of pills.

As for the stock, Novo Nordisk shares were down 1.05% at $42.51 in premarket trading on Monday. Nothing dramatic, but the market is digesting a lot of data at once.